Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 10/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.58 |
| ▸ | NPC1 | O15118 | 9/20 | 0.58 |
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 2/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972560 | 1.00 | EGFR (0.70) | EGFRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL30227615 | 0.99 | EGFR (0.69) | EGFRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL25255502 | 0.99 | EGFR (0.69) | EGFRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL25255808 | 0.99 | EGFR (0.69) | EGFRMEN1KMT2ANPC1RAB9A | |
| Lithium SCHEMBL30227618 | 0.99 | EGFR (0.69) | EGFRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL25225907 | 0.99 | EGFR (0.69) | EGFRMEN1KMT2ANPC1RAB9A | |
| Potassium SCHEMBL30173582 | 0.99 | EGFR (0.69) | EGFRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL887947 | 0.92 | EGFR (0.60) | EGFRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL15154326 | 0.91 | EGFR (0.59) | EGFRMEN1KMT2ANPC1RAB9A | |
| SCHEMBL15154333 | 0.91 | EGFR (0.59) | EGFRMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180140592-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. | 2018-05-24 | — | — | US | claimed |
| US-20170327464-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2017-11-16 | — | — | US | claimed |
| EP-3213636-A1 | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2017-09-06 | — | — | EP | claimed |
| US-20160279121-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMA (IL) | 2016-09-29 | — | — | US | claimed |
| EP-3056205-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2016-08-17 | — | — | EP | claimed |
| US-20160158216-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2016-06-09 | — | — | US | claimed |
| US-20160046582-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2016-02-18 | — | — | US | claimed |
| US-9233927-B2 | Crystals of laquinimod sodium and improved process for the manufacture thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2016-01-12 | — | — | US | claimed |
| US-9102620-B2 | Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2015-08-11 | — | — | US | claimed |
| US-8962598-B2 | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators | IMMUNAHR AB (SE) | 2015-02-24 | — | — | US | claimed |
| US-20140051723-A1 | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2014-02-20 | — | — | US | claimed |
| US-8580819-B2 | Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2013-11-12 | — | — | US | claimed |
| US-20130203703-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS | IMMUNAHR AB (SE) | 2013-08-08 | — | — | US | claimed |
| EP-2597954-A1 | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2013-06-05 | — | — | EP | claimed |
| EP-2590653-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | Teva Pharmaceutical Industries Ltd. (IL) | 2013-05-15 | — | — | EP | claimed |
| CN-102985090-A | 5-chloro-4-hydroxy-1-methyl-2-oxo-n-phenyl-1,2-dihydroquinoline-3-carboxamide, salts and uses thereof | TEVA PHARMA | 2013-03-20 | — | — | CN | claimed |
| US-20120010239-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | ACTIVE BIOTECH AB (SE) | 2012-01-12 | — | — | US | claimed |
| WO-2012006538-A1 | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-01-12 | — | — | WO | claimed |
| WO-2012006544-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2012-01-12 | — | — | WO | claimed |
| US-20120010238-A1 | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2012-01-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180140592-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | IDH2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR2C | EGFR 4236/4885MEN1 690/4885KMT2A 83/4885 |
| US-20160046582-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | HLA-DRB1, HAAO, RECQL | EGFR 4590/4885MEN1 3798/4885KMT2A 82/4885 |
| US-20140051723-A1 | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | HDHD5, DDAH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 3924/4885MEN1 1098/4885KMT2A 209/4885 |
| US-20170327464-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | POLQ, MTX1, MTX2 | EGFR 4716/4885MEN1 3789/4885KMT2A 15/4885 |
| US-20160158216-A1 | CRYSTALS OF LAQUINIMOD SODIUM AND IMPROVED PROCESS FOR THE MANUFACTURE THEREOF | POLQ, MTX1, TLR7 | EGFR 4709/4885MEN1 3899/4885KMT2A 15/4885 |
| US-20160279121-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | IDH2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR2C | EGFR 4236/4885MEN1 690/4885KMT2A 83/4885 |
| US-20130203703-A1 | 1,2-DIHYDRO-4-HYDROXY-2-OXO-QUINOLINE-3-CARBOXANILIDES AS AHR ACTIVATORS | AHR, HRH4, ARNT | EGFR 826/4885MEN1 3486/4885KMT2A 761/4885 |
| US-20120010238-A1 | DEUTERATED N-ETHYL-N-PHENYL-1,2-DIHYDRO-4-HYDROXY-5-CHLORO-1-METHYL-2-OXOQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | HDHD5, DDAH1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 3924/4885MEN1 1098/4885KMT2A 209/4885 |
| US-20120010239-A1 | 5-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF | IDH2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HTR2C | EGFR 4236/4885MEN1 690/4885KMT2A 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.